Navitoclax

Navitoclax is a BCL-XL/BCL-2 inhibitor that is being investigated to treat myelofibrosis.

Type of Molecule

Small Molecule

Target

BCL-XL/BCL-2

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted)
Myelofibrosis n/a
Phase 3